Clinical Trial Update: Bevacizumab and Lomustine for Recurrent GBM [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bevacizumab and lomustine for recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lomustine (Lomustine)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Glioblastoma Multiforme, Cognition Disorders | Phase 3 | Status: COMPLETED